Best in Class Biologic Therapeutics
OCMS Bio is an antibody discovery and engineering company laser focused on improving health outcomes of patients globally through the rapid discovery and optimization of the best possible antibody drugs.
PROBLEM
Since 1986, antibodies have been engaging previously ‘undruggable’ targets with precision. By 2023 seven out of the top ten best-selling drugs are antibodies.
That said, current antibody discovery and engineering methods remain suboptimal. “Approvable” medicines have side effects and suboptimal dosing, while the development costs and time outpace traditional small-molecule drugs.
Current processes are limited to discovering antibodies that adequately bind to their target (‘affinity’), and then transfer to mammalian cells to assess developability and function, such as neutralization of a virus or the blocking of a receptor.
This process, which can take years and millions of dollars, misses many better antibodies which would have resulted in easier dosing, fewer side-effects and enhanced efficacy.
SOLUTION
OCMS can -with speed and certainty- identify antibodies based on their ability to elicit a desired functional effect. The OCMS mammalian-cell screening eliminates the translation from non-mammalian to mammalian cells, which can cut years and millions from the development. It also deploys ‘function-first’ processes on unaltered antibodies measuring activity such as avidity and specificity screening for optimized drug candidates through lossless function-first high-throughput analysis. OCMS’ ‘function-first’ system allows for the discovery of best-in-class biologics that can overcome issues of safety, efficacy, and convenience where other methodologies are forced to stop short.
TECHNOLOGY
The practical benefits of the OCMS rapid antibody screening system include faster identification of high-affinity, functional antibodies by screening 100,000+ natural variants in parallel, preserving native heavy-light chain pairings for optimal stability and specificity. It eliminates the need for recombinant expression (translation), reducing time and cost while enabling direct “function-first” screening of antibodies against complex targets. This accelerates lead selection and improves success rates for therapeutic antibody development.
OCMS ANTIBODY PIPELINE
GLP-1 RECEPTOR AGONISTS CAUSE MUSCLE MASS LOSS AND WEIGHT REBOUND AFTER ENDING THERAPEUTIC COURSE
Muscle preservation for patients on GLP-1 therapy:
MAb Optimization Strategy: Balancing ActRIIA/ActRIIB blockade improves efficacy and simplifies CMC
Total Market Opportunity of ~$30B in US alone
OCMS NOVEL ANTIBODY DISCOVERY SOLUTION
Only the OCMS system provides high-throughput screening with unaltered mammalian antibodies, cutting years from development, reducing costs, and minimizing risk. It is also the only platform that enables ‘function-first’ testing to discover optimal antibody structures.
EXPERIENCED LEADERSHIP TEAM
Be Part of Our Vision!
Join OCMS Bio in revolutionizing antibody discovery and engineering. Our cutting-edge On-Cell mAb Screening (OCMS) technology accelerates the development of monoclonal antibodies, aiming to improve patient outcomes globally. Connect with us to explore collaborative opportunities and be part of advancing the next generation of antibody therapeutics.
